title: Heparin-induced thrombocytopenia and the health economic analysis of argatroban.
authors.affiliation: Anaesthesia and Intensive Care, University of Aberdeen, Aberdeen, UK.
authors.forename: D A
authors.initials: DA
authors.lastname: Coventry
authors.affiliation: Anaesthesia and Intensive Care, University of Aberdeen, Aberdeen, UK Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK n.r.webster@abdn.ac.uk.
authors.forename: N R
authors.initials: NR
authors.lastname: Webster
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D010875:Pipecolic Acids / Q000191:economics* / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy* / Q000191:economics; D006113:United Kingdom
chemical_list: D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban